CGRP monoclonal antibody antagonist

This page covers all CGRP monoclonal antibody antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Calcitonin gene-related peptide (CGRP), CGRP (Calcitonin Gene-Related Peptide).

Targets

Calcitonin gene-related peptide (CGRP) · CGRP (Calcitonin Gene-Related Peptide)

Marketed (3)

• erenumab-aooe · Amgen · Neurology
  Erenumab is a monoclonal antibody that binds to and blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.
• Fremanezumab Prefilled Syringe · Hospital Clínico Universitario de Valladolid · Neurology
  Fremanezumab is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.
• Fremanezumab Prefilled Syringe [Ajovy] · Beth Israel Deaconess Medical Center · Neurology
  Fremanezumab is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.

Phase 3 pipeline (3)

• ALD403 (Eptinezumab) · Alder Biopharmaceuticals, Inc. · Neurology
  Eptinezumab is a monoclonal antibody that binds to and blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.
• ALD403 · Alder Biopharmaceuticals, Inc. · Neurology
  ALD403 is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.
• Erenumab Dose 1 · Amgen · Neurology
  Erenumab is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.

Patent intelligence

• cgrp monoclonal antibody patent landscape — aggregated cliff calendar, attackable patents, originator estates